Qualigen Therapeutics Inc
For the period ended Dec 31, 2023. Filed Apr 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 8, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included on signature page)
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Michael S. Poirier and Christopher L. Lotz, and each of them individually, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments to this Annual Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Michael S. Poirier | Chairman of the Board, Chief Executive Officer | April 5, 2024 |
| Michael S. Poirier | (Principal Executive Officer) | |
| /s/ Christopher L. Lotz | Vice President of Finance, Chief Financial Officer | April 5, 2024 |
| Christopher L. Lotz | (Principal Financial and Accounting Officer) | |
| /s/ Richard A. David | Director | April 5, 2024 |
| Richard A. David | ||
| /s/ Sidney W. Emery, Jr. | Director | April 5, 2024 |
| Sidney W. Emery, Jr. | ||
| /s/ Matthew E. Korenberg | Director | April 5, 2024 |
| Matthew E. Korenberg | ||
| /s/ Kurt H. Kruger | Director | April 5, 2024 |
| Kurt H. Kruger | ||
| /s/ Ira E. Ritter | Director | April 5, 2024 |
| Ira E. Ritter | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.